FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2026-04-16
Summary
This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.
Conditions
- Triple-negative Breast Cancer
Interventions
- DRUG
-
A1: SHR-A1811
A1: an anti-HER2 antibody-drug conjugate (ADC)
- DRUG
-
A2: SHR-A1811 with Camrelizumab with famitinib
A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) Camrelizumab: an anti-programmed death-1 (PD-1) antibody
- DRUG
-
B1: TROP2 ADC
B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
- DRUG
-
B2: TROP2 ADC with Camrelizumab
B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC Camrelizumab: an anti-programmed death-1 (PD-1) antibody
- DRUG
-
C1: SHR-A1811
C1: an anti-HER2 antibody-drug conjugate (ADC)
- DRUG
-
C2: SHR-A1811 with BP102
C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)
- DRUG
-
D1: TROP2 ADC
D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
- DRUG
-
D2: TROP2 ADC with BP102
D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)
- DRUG
-
E1: SHR-A1811
E1: an anti-HER2 antibody-drug conjugate (ADC)
- DRUG
-
F1: TROP2 ADC
F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
- DRUG
-
G1: SHR-A1811
G1: an anti-HER2 antibody-drug conjugate (ADC)
- DRUG
-
H1: TROP2 ADC
H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
- DRUG
-
E2: SHR-A1811 with everolimus
E1: SHR-A1811 an anti-HER2 antibody-drug conjugate (ADC) everolimus： an mTOR inhibitor
- DRUG
-
TQB2102 with TQB2868
TQB2102: an anti-HER2 antibody-drug conjugate (ADC) TQB2868: an anti-PD-1/TGF-β bispecific antibody in all-comer TNBC
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Zhimin Shao, M.D. · Fudan University
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-30
- Primary Completion
- 2027-12-31
- Completion
- 2028-12-31
Countries
- China
Study Locations
More Related Trials
-
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06208033 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
NCT05383482 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
NCT05527821 ·Status: UNKNOWN ·Phase: PHASE2
-
Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer
NCT04828395 ·Status: UNKNOWN ·Phase: PHASE2
-
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
NCT04978012 ·Status: RECRUITING ·Phase: PHASE2
-
Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer
NCT05932264 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
NCT05265793 ·Status: UNKNOWN ·Phase: PHASE2
-
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
NCT06080854 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Investigate FP002 in Subjects With Advanced Malignancies
NCT05982080 ·Status: RECRUITING ·Phase: PHASE1
-
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
NCT06719700 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
NCT02183805 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors
NCT06131216 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer
NCT04818333 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC
NCT02012062 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT04734262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)
NCT00817583 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
NCT06754930 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma
NCT00816855 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy
NCT06313541 ·Status: RECRUITING ·Phase: PHASE2
-
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
NCT05894018 ·Status: RECRUITING ·Phase: PHASE2
-
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT05405595 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors
NCT00984997 ·Status: COMPLETED ·Phase: PHASE2
-
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
NCT03171220 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
NCT06055166 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC
NCT05888402 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2